BUB1B and cholangiocarcinoma: To further analyze the stronger evidence of prognostic factors for the short survival of patients with CCA, we combined the immunohistochemistry data of patients with CCA to analyze survival time and performed cox regression analysis that divided the expression of two molecules into four groups as follows: high BubR1 and MPS1 (21/152 cases, 14%), high BubR1 but low MPS1 (60/152 cases, 39%), high MPS1 but low BubR1 (27/152 cases, 18%), and low BubR1 and MPS1 (44/152 cases, 29%).